Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 130

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Pancreatic carcinoma metastatic

Not yet recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Plasma cell myeloma

Not yet recruiting

Dapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Instytut Hematologii I Transfuzjologii

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Gastrointestinal neuroendocrine tumour

Not yet recruiting

Study of Lutetium-177 and Yttrium-90 DOTATATE combination therapy for patients with inoperable gastrointestinal neuroendocrine tumors

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Narodowe Centrum Badan Jadrowych

Non-small cell lung cancer

Not yet recruiting

Study on the Effects and Safety of Cemiplimab and BNT116 in Adults with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Neoplasm

Not yet recruiting

Study of ATX-898 alone and in drug combination for patients with advanced solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Bladder transitional cell carcinoma stage I

Not yet recruiting

Efficacy of Enfortumab Vedotin plus Pembrolizumab in Adult Patients with Muscle‑Invasive Bladder Cancer Using a Bladder‑Sparing Response‑Adapted Approach

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neoplasm

Not yet recruiting

Phase 2 Study Evaluating Safety and Efficacy of Belzutifan in Adults with Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma+5

Not yet recruiting

Study of MDX2003 in Adults with Relapsed or Refractory B‑Cell Malignancies

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Breast cancer

Not yet recruiting

Effect of linzagolix and bilastine on breast density in premenopausal women at high risk of breast cancer: a phase II trial

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bilastine
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

Squamous cell carcinoma of head and neck+1

Not yet recruiting

Pharmacokinetic study of pembrolizumab and drug combination in patients with non‑small cell lung cancer or head and neck squamous cell carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Antoine Lacassagne

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.